IL6 and cancer: These findings together imply that TTRAP-derived IL-21 is a pleiotropic effector that can either facilitate or thwart tumor growth depending on the cytokine milieu in the tumor microenvironment, warranting careful consideration of the selective targeting of IL-6 or IL-21 for the treatment of cancer in the future.